Life Sciences IP Review

19/12/2025

The US Supreme Court will not review the Entresto case between MSN Pharmaceuticals and Novartis, declining to resolve what petitioners said was a “longstanding and significant conflict in patent law” regarding “after-arising technology.” On Monday, December 15, the court denied MSN’s petition for certiorari, in which it had asked for clarity on the issue of after-arising technology and patentability following its lengthy battle over the heart drug.

Read more... https://ow.ly/brVS50XM6H5

SCOTUS shuts the door on Entresto ‘after-arising technology’ review

19/12/2025

A UK appellate court has revived a critical patent for Abbott's continuous glucose monitoring (CGM) technology. The decision overturns a 2024 ruling that had previously revoked the patent, which covers a specialized integrated system for diabetes care.

Find out more: https://ow.ly/lQML50XM6zg

Abbott wins appeal to restore glucose monitoring patent

16/12/2025

A UK court is hearing claims that delays and construction inconsistencies led to the alleged wrongful invalidation of a key patent.

The case centres on Abbott’s glucose monitoring technology at the heart of a global dispute.

Read more: https://ow.ly/3H8a50XKtjE

Abbott appeals ‘baffling’ decision in glucose monitoring device feud

16/12/2025

The country aims to become the world’s third-largest life sciences economy by 2035, but stalled investment, regulatory hurdles and talent shortages are raising doubts over whether the target is achievable. The challenges are mounting.

Read more: https://ow.ly/cJrg50XKt7R

Diagnosis: What’s holding back UK life sciences?

11/12/2025

Teva Pharmaceuticals has pulled over 200 patents from the FDA’s Orange Book under FTC pressure, opening the door for generic competition.

The move marks one of the most significant clean-ups in recent years, reshaping the US generics landscape.

Read the full story here: https://ow.ly/zZ5n50XHveJ

Teva scrubs 200-plus Orange Book patents after FTC turns the screw

11/12/2025

Navigating bispecific antibody patents is no small feat—Benjamin Pelletier of Haynes Boone serves up a masterclass in the dos and don’ts of this global, high-stakes “kitchen.”

Every jurisdiction is a different recipe, and success means getting it right from the US to Latin America to the Persian Gulf.

Discover Pelletier’s full guide to mastering bsAb patent strategy: https://ow.ly/IOEh50XHuVv

Prosecuting bispecific antibody patents: A cookbook for patent chefs

10/12/2025

In Boston’s competitive life sciences ecosystem, IP assets are the foundation of billion-dollar valuations, breakthrough partnerships, and sustained market advantage.

LSPN North America Spring 2026 brings together leading investors, in-house counsel, and deal-makers to unpack the commercial IP strategies that maximize innovation value.

Join us April 29–30, 2026 in Boston to hear how the industry’s leading voices are solving these challenges in real time.

Secure your place today: https://ow.ly/UGmL50XGl9U

10/12/2025

Cooley has made a major play in life sciences, hiring a 30-plus patent counselling team from Dechert led by Andrea Reid, Andrew Wilkins and John Rearick—bringing deep biotechnology and pharmaceutical expertise under one roof.

Explore the full story: https://ow.ly/7sjI50XGHL3

Cooley drafts in 30-strong life sciences team from rival

10/12/2025

The US government is urging the Supreme Court to take up the high-stakes skinny label battle between Hikma and Amarin, warning that the Federal Circuit’s ruling could undermine the future of skinny labelling and restrict access to lower-cost generics.

Read the full story:

US govt backs Hikma over ‘skinny label’ rules

05/12/2025

Less than 24 hours left to save $700 on your ticket for the 8th Annual LSPN North America – Spring 2026 in Boston, April 29–30.

Join 350 IP professionals, including 50% in-house counsel, for actionable insights on:

-Pharmaceutical partnerships and licensing deals
- Optimising innovation protection strategies
- Streamlining patent operations for efficiency

Don’t miss this chance to connect with the who’s who of life sciences IP.

Register now: https://ow.ly/cGAv50XA5Ca

05/12/2025

New Year, New Categories, New Winners

We’ve just celebrated the standout individuals shaping life sciences IP in 2025—leaders whose vision, expertise, and impact set the benchmark for excellence.

This elite group includes:
• Mercedes Meyer (Banner Witcoff) – Inspiring Woman of the Year
• Jorge A. Goldstein (Sterne Kessler) – Lifetime Achievement Award
• John Desmarais (Desmarais) – Patent Litigator of the Year
• Karen Mangasarian (Haley Guiliano) – Patent Prosecutor of the Year
• Kerri-Ann Limbeek (Desmarais) – Rising Star of the Year

They’ve driven innovation, delivered landmark wins, and raised the bar for the entire profession.

Now it’s your turn to help shape the 2026 honours.

Nominations for the LSPN Awards 2026 (Individual Categories) are officially open.

If you know someone whose work deserves to stand alongside this distinguished group—
a visionary leader, a standout litigator, a strategic prosecutor, or a rising talent—now is the time.

Nominate them today: https://ow.ly/58I950XCBzy

05/12/2025

The Federal Circuit has overturned Seagen’s $41m jury win, ruling that its ADC patent lacked sufficient written description and enablement support.

The decision wipes out the verdict and raises fresh questions about the patent’s strength.

Discover what the ruling means for ADC patents: https://ow.ly/2oMG50XCByg

FedCirc voids Seagen patent in $41m cancer treatment dispute